GSE202755
RNA sequencing of LNCaP cells treated with castration and/or enzalutamide
The goal of this study was to determine how androgen receptor inhibition alters transcriptional programs in prostate cancer cells. LNCaP prostate cancer cells were grown in 10% charcoal-stripped serum (CSS) supplemented with 0.5 nanomolar dihydrotestosterone (DHT), in CSS without DHT modeling castration, with CSS + DHT but in the presence of 10 micromolar enzalutamide, or in CSS without DHT (castrated) and in the presence of enzalutamide for 72 hours. Analysis shows that androgen receptor target genes are reduced with castration, enzalutamide or the combination of castration + enzalutamide. Overall design: Comparative gene expression profiling analysis of RNA-seq data for LNCaP cells treated for 72 hours with castration, enzalutamide or castration + enzalutamide.